8:15 am Virtual Coffee Room Opens

Targeting Solid Tumors with Combination Approaches

8:30 am Harnessing the Next Wave of Immune Checkpoints to Enhance Cell Therapy in Solid Tumors

9:00 am Leveraging Immune-Adjuvants to Enhance T Cell Therapy in Solid Tumors

9:30 am Using Adaptive’s Immune Medicine Platform to Advance Cell Therapies in Oncology

  • Adria Carbo Director, Business Development, Adaptive Biotechnologies
  • Catherine Sanders VP Research Sales & Business Development, Adaptive Biotechnologies


  • Adaptive’s Immune Medicine Platform leverages proprietary chemistry, computational biology, and machine learning to read and understand patient’s immune systems.
  • Adaptive has developed a best-in-class, high-throughput T cell receptor (TCR) screening platform that allows the discovery of naturally-occurring, potent, ultra-low frequency TCRs with differentiated therapeutic potential.
  • The Adaptive TruTCR discovery engine has allowed the selection and characterization of several high avidity TCRs against clinically relevant targets, demonstrating improved cytolysis relative to benchmark TCRs and preliminary promising safety profile.

10:00 am Developing Parallel CAR-T for Increased Efficacy

10:30 am Morning Refreshments & Speed Networking

Harnessing Natural Immune Biology to Inform Multi-Targeted Strategies

Chair: Madan Jagasia

  • Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc.

11:30 am Targeting the Solid Tumor Microenvironment with Synergistic Therapy to Enhance T Cell Infiltration and Survival

  • Zhifen Yang Director of Preclinical Development, Refuge Biotechnologies

12:00 pm Leveraging TILs to Engage Solid Tumors as a Natural Multi-Targeted Approach

  • Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc.

12:20 pm CRISPR/Cas9 Engineered TIL for Supercharged T Cell Function

12:40 pm Expert Panel Q&A: Challenges, Strengths and Next Steps in Advancing TIL Therapies

1:00 pm Lunch & Networking

Leveraging Logic to Enhance Tumor-Specificity

1:30 pm Developing Engineering Solutions to Promote CAR-T Cell Safety and Function in the Tumor Microenvironment

  • Melita Irving Group Leader, Ludwig Institute for Cancer Research Lausanne

2:00 pm Developing Co-Stimulatory Domains to Create Robust, Target Cell-Specific Activation

  • Marco Ruella Assistant Professor of Medicine, University of Pennsylvania

2:30 pm Tmod: A Cell Therapy That Exploits Loss-of-Heterozygosity to Specifically Kill Tumor Cells

3:00 pm Pharmacological Control of CAR T Cell Therapies

3:30 pm Afternoon Networking

Tuned Tumor Killing with Synergistic Therapy

4:00 pm Targeting Multiple Antigens with Antibody-Redirected CARs Sequentially vs. Simultaneously

4:30 pm Employing Viral Combinations to Make Solid Tumors Vulnerable to CAR-T Therapy

5:00 pm Suppressing the Tumor Microenvironment with Combination Therapy to Enhance Anti-Tumor Efficacy in Solid Tumor Indications

  • Hong Ma SVP Clinical Development, CARsgen Therapeutics

5:30 pm Chair’s Closing Remarks

5:45 pm Close of Summit

On-Demand Content

Richard Boyd Cartherics

Richard Boyd


Cartherics Ltd.

Sculpting the Immune System Through Multi-Moiety Therapy

  • Investigating the therapeutic effects of infusion of multiple cell types derived from gene-edited iPSC cells; how important is histocompatibility? What role for combination with antibody modalities?
  • Describing the immune response and mechanistic rationale behind multi cell-type infusion, the role of each modality, and their multiplexed effects in vivo; how best to engage the patients endogenous immune system as a complementary anti-cancer defence?
  • Discussing clinical, manufacturing and regulatory challenges in implementing multi-moiety strategies such as toxicity, and
    understanding the additive effects of different cell types; expect the unexpected